Vanguard Group Inc. Raises Position in Cencora, Inc. (NYSE:COR)

Vanguard Group Inc. boosted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 0.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,301,978 shares of the company's stock after buying an additional 1,993 shares during the quarter. Vanguard Group Inc. owned 11.02% of Cencora worth $4,786,128,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in COR. State Street Corp grew its holdings in shares of Cencora by 3.8% in the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company's stock worth $1,810,970,000 after acquiring an additional 291,867 shares during the period. Wellington Management Group LLP increased its position in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after buying an additional 338,452 shares in the last quarter. Boston Partners raised its stake in shares of Cencora by 2.6% during the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock worth $1,128,058,000 after buying an additional 125,611 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Cencora by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company's stock worth $941,183,000 after buying an additional 189,054 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in shares of Cencora by 6.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock worth $495,249,000 after buying an additional 138,868 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Cencora Trading Up 0.3 %

COR traded up $0.86 during midday trading on Thursday, hitting $272.25. The company's stock had a trading volume of 201,501 shares, compared to its average volume of 1,582,963. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $273.60. The firm has a 50-day moving average price of $252.47 and a two-hundred day moving average price of $240.68. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $52.79 billion, a P/E ratio of 38.73, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.81%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average price target of $280.20.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.